Six US IPOs were able to raise $970 million last week including two $330 million + deals. Three IPOs offered double-digit first-day pops, including e-commerce...read more
Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised $25 million by offering 3.1 million shares at $8. The company had planned to offer 2.3 million shares at $10 to $12; total proceeds were $25 million, as expected. Alcobra plans to...read more
Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised the proposed deal size for its upcoming IPO on Wednesday. The Tel Aviv, Israel-based company now plans to raise $25 million by offering 2.3 million shares at a price range of $10...read more
US IPO Recap: IPO market continues torrid pace with six pricings, 12 new filers
Six US IPOs were able to raise $970 million last week including two $330 million + deals. Three IPOs offered double-digit first-day pops, including e-commerce...read more
Alcobra prices upsized IPO at $8, below the range
Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised $25 million by offering 3.1 million shares at $8. The company had planned to offer 2.3 million shares at $10 to $12; total proceeds were $25 million, as expected. Alcobra plans to...read more
6 US IPOs planned for the week of May 20
The following IPOs are expected to price this week: Alcobra (ADHD), an Israeli drug company developing a non-stimulant ADHD treatment, plans to raise $25 million by...read more
Israeli ADHD drug developer Alcobra increases proposed IPO deal size to $25mm
Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised the proposed deal size for its upcoming IPO on Wednesday. The Tel Aviv, Israel-based company now plans to raise $25 million by offering 2.3 million shares at a price range of $10...read more